Answers are grounded in this paper and cite their sources.
Nanoparticles improve motor and cognitive deficits in Parkinson's disease, suggesting a novel treatment approach.
In Parkinson’s disease (PD), the abnormal aggregation of α-synuclein (α-Syn) and oxidative stress form a self-reinforcing vicious cycle that is a key driver of disease progression. To disrupt this pathogenic loop, this study designed and synthesized zinc-tannic acid coordination nanoparticles (Zn-TA NPs). Zn-TA NPs exhibit potent reactive oxygen species (ROS) scavenging capability and can concurrently inhibit α-Syn fibril formation and disaggregate α-Syn fibrils. In cellular models, Zn-TA NPs scavenged ROS, preserved mitochondrial function, and demonstrated neuroprotective effects. In a PD mouse model, treatment with Zn-TA NPs significantly improved motor and cognitive deficits, attenuated dopaminergic neuron loss, and reduced cerebral levels of α-Syn pathological deposition, oxidative stress, and neuroinflammation, without inducing significant systemic toxicity. These findings indicate that Zn-TA NPs exert multitarget neuroprotective effects by synergistically modulating α-Syn aggregation and oxidative stress, offering a novel strategy based on natural polyphenol-metal coordination for the treatment of neurodegenerative diseases.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: